Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Dimensional Fund Advisors LP grew its stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 143.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 118,995 shares of the biotechnology company’s stock after acquiring an additional 70,190 shares during the quarter. Dimensional Fund Advisors LP owned about 0.30% of Oramed Pharmaceuticals worth $288,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ORMP. Peapod Lane Capital LLC purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter valued at $550,000. World Equity Group Inc. purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter valued at $48,000. Finally, BML Capital Management LLC increased its holdings in shares of Oramed Pharmaceuticals by 20.9% in the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after acquiring an additional 457,716 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Price Performance

Oramed Pharmaceuticals stock opened at $2.15 on Friday. The stock has a market capitalization of $87.83 million, a price-to-earnings ratio of 19.55 and a beta of 1.65. Oramed Pharmaceuticals Inc. has a 1-year low of $1.82 and a 1-year high of $3.09. The business has a fifty day moving average price of $2.25 and a 200-day moving average price of $2.31.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.16). The firm had revenue of $2.00 million during the quarter. On average, equities research analysts anticipate that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.